2024
01 January 2024
-
Suspicion of rare eye condition from Ozempic use to be investigated further
| 17 January 2025 |
The Danish Medicines Agency will request the European Pharmacovigilance Risk Assessment Commit-tee, PRAC, to assess two new Danish register-based studies from the University of Southern Denmark. The studies point to a potential increased risk of a rare eye condition, NAION, in patients receiving the diabetes medicine Ozempic.
-
Update: Information meeting on the revised ICH GCP guideline (ICH E6 R3)
| 16 January 2025 |
The Danish Medicines Agency will hold after-work meetings on the revised ICH GCP guideline (ICH E6 R3) on February 27 and 28, 2025, from 14:30 to 18:00.